
Mendus Q4 2024 - Getting closer to pivotal-stage readiness

Redeye provides its comment on Mendus' Q4 2024 report. We judge the company is making solid progress towards its goal of being ready for pivotal trials with vididencel in AML as soon as H2 2025e. We believe updated ADVANCE II survival data at ASH 2024 and positive regulatory feedback bode well for Mendus' clinical and business development prospects. We update our estimates and valuation.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Mendus Q4 2024 - Getting closer to pivotal-stage readiness](#)